Rize Oncology develops a platform that allows to conjugate or tether donor DNA templates.
Rize Oncology has raised $358K in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.
Rize Oncology's investors include William Garner, André Pereira Fraga Figueiredo.
Rize Oncology is headquartered in Kelowna, Canada.
Rize Oncology develops a platform that allows to conjugate or tether donor DNA templates.
Rize Oncology is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rize Oncology — Funding & Investors." VCBacked, October 30, 2025, https://www.vcbacked.co/company/rize-oncology. Accessed August 17, 2026.
VCBacked. (2025). Rize Oncology — Funding & Investors. Retrieved August 17, 2026, from https://www.vcbacked.co/company/rize-oncology
{{cite web |title=Rize Oncology — Funding & Investors |url=https://www.vcbacked.co/company/rize-oncology |website=VCBacked |access-date=August 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated